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Abstract 
The abuse of illicit drugs is a major social and health problem. In fact, illicit drugs are responsible 
of many adverse systemic effects which may require urgent medical treatment. In the present 
review we report details on the prevalence of the major illicit drugs abused in Europe in 2009, 
according to the report of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), focusing on the effects on the cardiovascular system, including sudden cardiac death.  
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Epidemiology of illicit drug abuse in Europe 
The abuse of illicit drugs is a major social and health problem. In fact the United Nations 
Observatory (UNODC) 1 reports that in 2009 between 3.3% and 6.1% of the worldwide population 
aged 15-64 admitted to have used illicit substances at least once during the previous year. Based on 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)2, Europe is attributed a 
similar prevalence of drug abuse, and quotes, following the past decades reporting amazing raises, 
seem unfortunately stable. 
In details, Cannabis is by far the most frequently abused illicit substance (Figure 1). Lifetime 
prevalence is 10% to 30% of the population aged 15-64, and 6.7% in this age range used it at least 
once in 2009 in Europe2. Cannabis use is mainly concentrated among young people (15-34 years) in 
which the prevalence is 12.1% during 2009. Males are most likely to use this substance than 
females, while Italy, Czech Republic and Spain are the countries with the highest prevalence of 
abusers. 
Cocaine is the second most used drug in Europe, with a lifetime prevalence of 4.3% among 
population aged 15-64 and 5.9% among population aged 15-34. Its last-year prevalence is estimated 
1.2% of the population aged 15-64 and 2.1% of the population aged 15-34. Also concerning this 
substance males are more frequently users than females, with higher prevalence in Spain, UK, Italy 
and Ireland. Of note, cocaine is often used in association with other illicit drugs, especially cannabis 
and alcohol. Among synthetic recreational drugs, amphetamines and ecstasy (3,4-methylenedioxy-
methamphetamine, MDMA) are the most commonly nowadays abused in Europe. Besides these, 
new synthetic stimulant and hallucinogenic drugs are continuously spreading worldwide especially 
among young people for their psychotropic effects including mood elevation, increased emotional 
sensitivity and closeness to others. Amphetamines use in 2009 is estimated in Europe about 0.5% of 
the population aged 15-64 and 1.1% of the population aged 15-34, and their use is larger in UK and 
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Northern Europe. Their estimated lifetime use in European population aged 15-64 is 3.8%. 
Concerning ecstasy, estimates of lifetime prevalence are 3.2% among the population aged 15-64, 
while last-year prevalence is 0.7% of the population aged 15-64 and 1.4% of the population aged 
15-34. Its use is more frequent in UK, Ireland, Czech Republic and Slovakia. Eventually heroin and 
other opiates remain a social problem in European countries, although use is decreasing due to the 
fear of diseases transmittable by syringes, like AIDS and hepatitis. Estimates of their lifetime 
prevalence are less reliable compared to other substances, but should roughly reach about 4 people 
per 1000 population aged 15-64, with a similar last-year prevalence among population aged 15-64 
and 15-34. Despite the low prevalence, however, these drugs are strongly problematic because of 
their strong physical and psychological dependence, and the frequent medical complications related 
to their use. 
Aiming to estimate the diffusion of these substances among students, the European School Survey 
Project on Alcohol and Other Drugs (ESPAD)3 reports that 18% of students aged 15-16 years have 
used illicit drugs at least once in their life, mainly Cannabis (13%) but also other substances such as 
cocaine and synthetic recreational drugs (6%), highlighting the important diffusion of this 
phenomenon among the youngest.  
 
Cardiovascular toxicity of illicit drugs 
Illicit drugs are responsible of many adverse systemic effects, which may require urgent medical 
treatment. In the following we focus on their effects on the cardiovascular system (Table 1). 
Cannabis 
Cannabis is usually smoked and rapidly absorbed through the lung. Its absorption is slow and 
variable, for this reason its effects are less predictable than other abuse substances. The toxic 
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potential of cannabis is generally considered low, but the wide diffusion and consistent use of this 
substance as a recreational drug determines considerable adverse effects4, 5. Although the most 
frequent are neurological side effects, the cardiovascular system is also affected due to the biphasic 
effect on the autonomic nervous system. At low or moderate doses cannabis increases sympathetic 
activity and reduces parasympathetic activity, while at high doses leads to the opposite effect, with 
a parasympathetic activation and sympathetic inhibition6. Cannabis, as a consequence of the effect 
on action potentials and refractory periods durations7 in the atria, favors automaticity, triggered 
activity and micro-re-entry8, 9 leading to atrial arrhythmias such as premature contractions, atrial 
flutter or fibrillation10. Cannabis may also lead to ventricular premature contractions and ST-T 
segment alterations on ECG11. Due to an interference with the integrity of the peripheral vascular 
reflex responses which protect myocites from ischaemia, and coronary vasospasm, also a few cases 
of acute myocardial infarction have been associated to cannabis use12. Eventually peripheral 
arteritis13, similar to Burger disease, may be found in heavy cannabis smokers. Of note, all these 
cardiovascular effects are potentiated when cannabis is assumed with other substances as cocaine, 
alcohol or amphetamines.  
Cocaine 
Cocaine is quickly absorbed from all mucous membranes of the body, so it can be smoked, injected 
or most frequently inhaled. Its systemic toxicity, especially neurological and cardiovascular, is well 
known and largely described. Its effects on the cardiovascular system are mediated by the inhibition 
of catecholamine reuptake at sympathetic nerve terminals, the stimulation of central sympathetic 
outflow and the increased sensitivity of adrenergic nerve terminals to noradrenalin14, 15. By 
increasing blood pressure and heart rate, prolonged use induces left ventricular hypertrophy16 and 
premature atherosclerosis17. Cocaine also promotes vasoconstriction and thrombosis through the 
enhanced release of endothelin-118, fibrinogen and von Willebrand factor19, the inhibition of nitric 
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oxide synthesis20, and the promotion of platelets activation and aggregation21, provoking an 
increased risk of acute myocardial infarction, even in users without atherosclerotic plaques22, 23, 24. 
Cocaine has also been involved in the development of myocarditis25, myocite necrosis26 and 
spontaneous aortic or coronary dissections27. Cardiac arrhythmias28 due to a direct action on ionic 
channels29, 30 are another relevant effect of cocaine abuse. Cocaine inhibits voltage-gated Nav1.5 
sodium channels31, leading to a reduction in myocardial conduction velocity32  and prolongation of 
QT interval on the ECG33, a risk factor for ventricular arrhythmias such as ventricular tachycardia 
and torsades de pointes30, 34. Cocaine also blocks potassium channels hERG35, which are responsible 
for Ikr repolarizing current36, resulting in a complex electrophysiological substrate predisposing to 
cardiac arrhythmias; these effects may obviously also precipitate latent pro-arrhythmic genetic 
alterations such as Long-QT37 and Brugada Syndromes38. In addition, cocaine abusers often assume 
alcohol aiming to slow cocaine’s metabolism and prolong the psychotropic effects. The 
combination of cocaine and ethanol leads to the formation of a metabolite, cocaethylene, which by 
itself slows cardiac conduction, delays repolarization and strongly inhibits both Nav1.5 sodium and 
hERG potassium channels39, 40. Cocaethylene inhibition of cardiac ion channels is in fact the main 
cause of the increased incidence of arrhythmias associated with the combined use of cocaine and 
alcohol41. 
Amphetamines  and ecstasy 
Ecstasy, or MDMA, is a synthetic derivative of amphetamine which can be assumed orally as 
pillows. The main adverse effects of this drug are neurological, related to the release of serotonin, 
dopamine and noradrenalin from the monoamine neurons42, leading to a long-term depletion of 
these neurotransmitters. Effects begin after about 30 minutes and can last up to 5-6 hours after 
assumption. Concerning cardiovascular toxicity, complications are mainly related to a sympathetic 
stimulation, leading to an increase in blood pressure and heart rate. The induced vasospasm and 
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thrombosis, in part also mediated by an indirect effect of toxic metabolites43, may cause acute 
myocardial infarction, supraventricular or ventricular arrhythmias and sudden cardiac death44, 45. 
Another recently discovered mechanism is the activation of 5-HT2B serotoninergic receptors, 
possibly leading to pulmonary hypertension and valvular heart disease46.  
Amphetamine and methamphetamine are assumed orally, but can also be inhaled or injected. These 
substances present neurological toxicity and several dangerous cardiovascular responses47 due to 
sympathetic activation. Myocardial infarction may be secondary to vasospasm and thrombosis45, 48, 
and sudden cardiac death to cardiac arrhythmias induced both directly and through long-lasting 
metabolites47, 49. As for other abuse substances, amphetamine’s toxicity is strongly potentiated by 
concomitant alcohol intake50. 
Stimulant and hallucinogenic drugs 
Eventually hallucinogenic substances, in particular d-Lysergic Acid Diethylamide (LSD) and 
psilocybin are ingested orally. Their mechanisms of action, lasting about 4-5 hours, are complex 
and include agonist, partial agonist, and antagonist effects at various serotonin, dopamine and 
adrenergic receptors, leading to important neurologic and psychotropic effects51. The adrenergic 
effects are usually mild, lower than what can occur after taking cocaine, amphetamine or ecstasy. 
Cardiovascular complications are rarely serious, although occasional attacks of supraventricular 
tachyarrhythmias and myocardial infarction due to serotonin induced platelet activation and 
sympathetic induced arterial vasospasm52 have been reported. 
Heroin 
Heroin (diacetylmorphine) is a semisynthetic analogue of morphine, which is slowly metabolized to 
morphine after its assumption, and rapidly produces a well-recognized syndrome of euphoria, 
miosis, respiratory and central nervous system depression, due to the increase in parasympathetic 
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activity. Cardiovascular effects are common as a consequence of the action on the vasomotor centre 
provoking bradycardia and hypotension. Drug-induced bradycardia along with enhanced 
automaticity can induce ectopic activity, atrial fibrillation, idioventricular rhythm, or potentially 
lethal ventricular tachyarrhythmias53. 
Other opiates 
Other opiates (such as dextropropoxyphene) have additional sodium channel blocking effects, 
which further contribute to the proarrhythmic54 and myocardial depressant55 effects, leading to 
acute left ventricular dysfunction and pulmonary oedema. Overdose of narcotic analgesics can also 
cause non-cardiogenic pulmonary oedema56 secondary to several reasons (anaphylactic reaction to 
the drug, increase in pulmonary capillary hydrostatic pressure by hypoxia induced pulmonary 
vasoconstriction, alveolar capillary membrane disruption). 
 
Drug abuse and sudden cardiac death: current literature 
Sudden cardiac death (SCD) is a death occurring within an hour of the onset of symptoms57. 
Epidemiological data are related to the prevalence of coronary heart disease, its major cause. The 
proportion of SCD within all deaths is estimated about 13%, with an incidence in Europe between 
0.36 to 1.28 per 1000 inhabitants per year57, 58. 
As previously stated, the majority of SCDs are related to coronary artery disease, but other relevant 
reasons may be cardiomyopathies or genetic arrhythmogenic diseases, such as channelopaties 
(Brugada, Long-QT and Short-QT Syndromes). Many SCDs unfortunately remain unexplained, 
especially those within young subjects without a clear predisposing substrate; given the above 
reported epidemiology and the mentioned cardiovascular toxicity evidences of drug abuse, some of 
them may be attributed to illicit drugs. In fact, the  UNODC reports between 23.1 and 58.7 deaths 
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per million inhabitants aged 15-64 due to illicit drug abuse worldwide, and about a half of them are 
SCDs1. 
In Europe, the average mortality rate due to overdose of illicit drugs is estimated between 4 and 59 
deaths per million population aged 15–64 years (Figure 2). The majority of these deaths are among 
young people, with a median age of about 35 years, and often present as SCDs2. Frequently a poly-
drug abuse is involved, especially when heroin is associated with cocaine, ethanol or 
benzodiazepines59, 60. 
The real prevalence of SCDs due to drug abuse has not been systematically assessed in large studies, 
but many reports of fatalities in abusers have been published (Table 1).  
As mentioned before, cannabis has a relatively low toxic potential, but a few cases of SCD have 
been reported after cannabis assumption, both alone61, 62 than associated with other drugs such as 
cocaine or amphetamines63, 64. 
A wider body of evidence is available instead on cocaine. Cocaine has the potential to provoke 
cardiac arrest through many mechanisms, therefore cases of massive myocardial infarction due to 
coronary thrombosis or vasospasm65, acute aortic or coronary dissection27, acute systemic 
thrombosis66 and ventricular arrhythmias, leading to ventricular fibrillation and SCD may be found. 
Twenty-two cases of cardiac arrest after crack cocaine smoking are reported by Hsue et al.67. In a 
large Spanish study cocaine use has been associated with 3% of total SCDs68, and another study 
suggested a 6-fold higher risk for SCD in cocaine abusers compared to the general population69. 
Darke et al. reported 83 cocaine-related cardiovascular deaths over 146 cocaine-related fatalities70. 
Cases of asystole and ventricular fibrillation71, 72, 73 have also been reported related to the induction 
of Brugada patterns on the ECG74, 75 or torsades de pointes in patients with known Long-QT 
Syndrome37. Despite the common induction of tachyarrhythmias as cause of SCD in cocaine users, 
also a case of syncope related to bradyarrhythmia76 has been reported. The contemporary 
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assumption of other drugs, especially heroin70, 77, or ethanol78, can potentiate these effects, leading 
to a higher risk of sudden fatalities.  
Amphetamine, methamphetamine and MDMA have also been implicated in some cases of  SCD, 
both alone79, 80, 81, 82, 83 than in association with cocaine or alcohol84. 
Obviously heroin can lead to SCD85, 86, 87 through the depression of respiratory and cardiovascular 
centres in the central nervous system, causing asystole and cardiac arrest. In fact, despite its lower 
prevalence compared to other drugs, heroin abuse is frequently related to life threatening 
complications.  
 
How to face the challenge? 
Given the epidemics of drug abuse together with the evidence of the related cardiovascular toxicity, 
illicit substances should necessary be searched for at least within young adults with cardiovascular 
disorders. The majority of drugs of abuse present a short half-life, but their use can be traced 
through their metabolites, with much longer half-lifes than the primitive substance.  
Cannabis (whose active component is ∆ 9-tetrahydrocannabinol) has a plasma half life of 20–30 
hours and can be detected in urine for several days in occasional users, and for up to two months in 
heavy users88, 89. Cocaine has a short serum half life (30–80 minutes), and is mainly metabolized 
and excreted in urine over a two week period, so its metabolites (the most important are 
benzoilecgonine and ecgonine methyl-ester) are reliable markers of a recent assumption88. Another 
metabolite, cocaethylene, presents a half-life of several days and is useful to detect the dangerous 
concomitant assumption of cocaine and alcohol. Amphetamine, methamphetamine and their 
metabolites (in particular methylenedioxy-amphetamine) can be detected in urine for several days 
after assumption, and their excretion is prolonged after administration of larger doses or in the 
12 
 
presence of alkaline urines88. MDMA is metabolized by the liver and excreted by the kidney for 
several days after assumption, so its recent use is easily traceable in the urine, both in its native 
form than through metabolites88. Morphine (the main heroin active metabolite) has a plasma half-
life of 2-3 hours and undergoes rapid hepatic metabolism. Metabolites are excreted in urine, and 
despite duration of renal excretion is highly variable and affected by the dose, chemical 
composition of street preparations, user’s previous drug habits, and individual variations in renal 
and hepatic function, they may be detected for up to 48 hours in occasional users and several days 
in chronic users88.  
All the aforementioned substances can also be traced using hair analysis, which provides a longer 
window of detection, typically 1 to 3 months according to the substance examined90, compared to 
urine analysis. Hair analysis, in fact, provides a very useful tool to search for long-term abuse91, but 
is surely more expensive than urine analysis that remains the most valid option to trace recent, acute 
substance assumption92. 
Previous experiences using systematic toxicological screening have in fact provided interesting 
results. Lucena et al.68 in an autoptic study on 668 population, analyzed blood and urine samples 
searching for cocaine, benzoilecgonine, cocaethylene, methylenedioxy-amphetamine (an 
amphetamine metabolite), MDMA, morphine, ∆ 9-tetrahydrocannabinol (cannabis), and ethanol. 
Cocaine metabolites and cocaethylene were present in about 3% of the total population, suggesting 
a non irrelevant role of drug abuse in SCDs.  
 
Conclusion 
Illicit drug abuse is common in Europe and most probably underestimated, especially among young 
adults. Recognize, treat and possibly prevent the adverse effects of these substances, which may 
lead to important cardiovascular and systemic complications, should become an aim for the 
cardiologist. For this reason, we suggest toxicological screening protocols with urine analysis, and 
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possibly hair analysis, for young adults with cardiovascular disorders and without recognizable 
structural or functional cardiac diseases, focusing at least on the most frequently abused and most 
toxic substances. By this approach a more precise definition of the risk profile of each illicit drug 
may be drawn and public health initiatives preventing specific illicit drug abuse may be improved. 
Furthermore evidence of drug abuse as a cause of aborted SCD may surely help to direct therapeutic 
options (e.g. implantable cardiac defibrillator) only to those individuals proving the ability to stop 
their addiction.  
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Table 1. Commonly abused substances in Europe with side effect’s mechanisms, major cardiovascular complications and reported sudden cardiac 
deaths. 
Substance Mechanisms Cardiovascular complications Reported SCDs 
Cannabis Biphasic: 
sympathetic-like at low doses 
parasympathetic-like at high doses 
Supraventricular arrhythmias 
Hypotension, bradycardia 
Ref. 9, 61, 62, 63, 64. 
Cocaine Inhibits reuptake of catecholamines 
Sympathetic-like 
Blocks Na+ (Nav1.5) channels 
Blocks K+ (hERG) channels 
Hypertension, left ventricular hypertrophy  
Vasospasm, thrombosis and myocardial infarction 
Atrial and ventricular arrhythmias 
Myocarditis and necrosis 
Ref.  27, 28, 37,  63, 64, 
65, 66, 67, 68, 69, 70, 
71, 72, 73, 74, 75, 77.  
Amphetamine Release of dopamine and noradrenalin 
(sympathetic-like) 
Vasospasm, thrombosis and myocardial infarction 
Arrhythmias 
Ref. 69, 79, 80, 81, 83. 
Ecstasy Release of serotonin, dopamine and 
noradrenalin (sympathetic-like) 
Vasospasm, myocardial infarction 
Arrhythmias 
Pulmonary oedema 
Ref. 44, 49, 69, 82, 84. 
 
Hallucinogenic drugs Serotoninergic, dopaminergic and 
adrenergic activity 
Hypertension 
Arrhythmias 
Vasospasm, myocardial ischemia 
Ref. 51, 52. 
Heroin - opiates Vasomotor centre depression 
(parasympathetic-like) 
Histamine release 
Bradyarrhythmias, hypotension 
Supraventricular and ventricular arrhythmias 
Pulmonary oedema 
Ref. 59, 60, 77, 85, 86, 
87. 
15 
 
Figure 1. Estimated lifetime prevalence (aged 15-64: black bars) and last-year (2009) prevalence 
among different population groups (aged 15-64: grey bars; aged 15-34: white bars) of the most 
commonly used illicit substances. Adapted from Ref. 2. 
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Figure 2. Estimated drug-induced deaths per million inhabitants among all adults aged 15-64 in 
Europe in 2009 (A) and estimated percentage of drug-related deaths among all deaths occurring in 
the population up to the age of 24 years (B). Adapted from Ref. 2. 
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